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lobal Differences in the
utcome of Heart Failure
mplications for Clinical Practice*
hilip A. Poole-Wilson, MB, MD,
RCP, FMEDSCI, FACC
ondon, United Kingdom
he diagnosis, management, and treatment of heart failure
n clinical practice is guided by evidence accrued from
igh-quality clinical trials, cohort studies, epidemiological
tudies, observational data, and a consensus of clinical
xperience. Recommendations are proffered in many guide-
ines from the continents of the world (1–5). Patients
enefit from adherence to guidelines (6,7) and appropriate
reatment. The expectation would be that medical practice
ould be similar, or almost so, in all parts of the world. Any
ifferences, which exist not only in heart failure, but also in
any other cardiovascular disorders (8–10), would be ac-
ounted for by simple clinical variables. If that were so, and
t is not (11,12), then outcomes measured as mortality,
orbidity, use of procedures, or hospitalization would be
niversally similar, and measurement of those outcomes
ould provide an indicator of performance, which would
ave validity within regions of a particular country, between
ountries, and between continents. What nirvana that
ould be for providers of health care. But the reality is
therwise.
See page 1640
For many years, researchers in the field of heart failure
ave sought to identify which patient characteristics predict
rognosis, using data from registries, patient cohorts, and
arge clinical trials. An obvious example of the clinical use of
uch an approach is the selection of patients for heart
ransplantation. A further ambition has been to identify
ubgroups of patients who might respond more favorably to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiac Medicine, National Heart and Lung Institute,
mperial College London, London, United Kingdom. Dr. Poole-Wilson was the
resident of the World Heart Federation 2003 and 2004, chair of a WHO Task Force
n the Definition of Myocardial Infarction (2008), member of the guidelineso
ommittee on Heart Failure of the European Society of Cardiology (2008), and a
ember of an Advisory Panel to Health Consumer Powerhouse (2008).particular treatment or management strategy. The findings
rom such analyses depend critically on what baseline
ariables have been included and on the known limitations
f subgroup analysis (13,14). A common procedure is to
nclude in a multivariate analysis only those variables that
ad a positive association in a univariate analysis. That may
iss the possibility that some combination of more easily
btainable characteristics would have at least as good a
redictive value as a single but expensive or complex
haracteristic. Any variable that correlates with New York
eart Association functional class or the severity of heart
ailure is likely to predict outcome. It is almost a tautology.
eart failure is a progressive disease so that the presence of
eart failure predicts worsening heart failure, which, in turn,
redicts advanced heart failure and death. The major criteria
redicting outcome can usefully be grouped into measures
f heart structure (heart size or ejection fraction in those
ith enlarged hearts, systolic heart failure), measures of
ardiovascular performance (such as maximal exercise ca-
acity or the 6-min walk test), and measures of the body
esponse (the simplest are renal function and the plasma
odium) (15). Adjustments are often made for a large
umber of variables in an attempt to remove any variance in
he response to an intervention that might be attributable to
mall differences in the baseline characteristics. A major
haracteristic, ejection fraction, is often misassessed in this
ype of analysis because the database may have only included
atients with large hearts (low ejection fraction, systolic
eart failure), excluding patients with normal-sized hearts
heart failure with a small heart, often referred to as diastolic
eart failure). A second key characteristic where differences
ay arise is gender (16), and that is not just problematic in
eart failure, since in several recent trials of intervention in
ardiovascular medicine, the response in women has been
nexpected (17). A third and vital characteristic is geogra-
hy. Geography becomes important because it reflects race,
thnicity, social circumstances, health resources, and cul-
ural attitudes; such variables impact on health delivery and
hus outcomes. In many analyses, patients are included who
ome from different continents across the globe (18).
Geographical variability is examined in the paper by Blair
t al. (19) in this issue of the Journal. The paper reports the
esults of the EVEREST (Efficacy of Vasopressin Antago-
ism in Heart Failure: Outcome Study with Tolvaptan)
rial, which tested the idea that short-term treatment with a
asopressin antagonist, tolvaptan, would be useful in the
reatment of patients admitted to the hospital with wors-
ning heart failure. At 7 days, or discharge from the hospital
f earlier, there was no difference in patient-assessed global
linical status but there was a greater reduction in body
eight. At a mean follow-up of 9.9 months, no beneficial
ffects were observed, the 2 primary end points being
ll-cause mortality and the composite of cardiovascular
eath or hospitalization for heart failure. Large clinical trials
f this sort require the enrollment of many centers (359
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Global Differences in the Outcome of HF November 11, 2008:1649–51ites, 1,251, 699, 5,641, and 619 patients, respectively, in
orth America, South America, Western Europe, and
astern Europe in the EVEREST trial). The baseline
haracteristics and treatment showed more uniformity and
dherence to guidelines than in earlier similar studies (20).
surprising finding in view of the lack of evidence is the
mall but much greater use of positive inotropic drugs in
orth America. The authors adjusted for baseline charac-
eristics. Before adjustment, mortality was similar in the
mericas and Western Europe but markedly less in Eastern
urope (numerically younger, higher ejection fraction,
ower serum creatinine, lower median B-type natriuretic
eptide, less intervention, and more atrial fibrillation). After
djustment, only South America stood out as having a high
ortality. The impact on change in global status at day 7 or
ischarge was not different in the regions of the world.
lthough statistically the p value for interaction was 0.02,
he slightly lower loss of weight in patients from South
merica may have limited clinical meaning.
Adjustments were made for race, which has been impli-
ated in some studies in patients with heart failure (21–24)
ut not others (25–28). Race should not be confused with
thnicity; race is largely related to genetics, whereas ethnic-
ty includes social and cultural differences. As people move
etween continents, race will not change, but ethnicity may
e altered even in unanticipated directions.
The type of analysis used in this paper has limitations that
re critical to the interpretation of the data. The dangers of
ubgrouping and the issue of generalizability need emphasis
13,14,29). Adjustment is made only for characteristics that
re well understood and can easily be measured. Other
haracteristics influence observed differences in outcomes
etween continents and are far more subtle and difficult to
easure. These include medical attitudes of physicians,
hich could determine previous care; differences in the
pproach to diagnosis and etiology; availability of resources;
ealth policies (30); and social and cultural circumstances.
onsiderable variation exists across continents in access to
edical care, the reasons for hospital admission, prevention
trategies, equity in the delivery care, financing of medical
are, drug availability, and procedural outcomes. What is
vident from this report is that some of these factors, and
he specific factors are not identified, may have a substantial
mpact. A consequence is that comparing outcomes across
ontinents almost certainly does not answer the question as
o whether care is of an equal standard between continents.
orse, the same problem arises among countries in the
ame continent. This has been demonstrated in the U.S.
31), Canada (32), and Europe (33). Within a country and
etween hospitals, only where economic, social, and cultural
ifferences are minimal can conventional outcomes be com-
ared and used for the purposes of assessing performance.
There are 3 important implications of this work. The first
s that researchers designing large clinical trials need to take
ccount of differences in outcomes between continents;
hese may influence the power calculation and the defini-
1ions used for particular outcomes. Second, if the result of a
rial is to be applied globally, experience from centers in
everal continents is advisable. Health authorities and drug
egulators may be uncertain about approving drug usage in
ne continent when the trial has been largely conducted in
nother (34). Third, and of the greatest importance, there is
need to study the social origins of heart failure and the
mpact of systems for health delivery. This will require more
areful description of end points other than mortality, such
s hospitalization and measures relating to quality of life and
he determinants of health delivery. Establishing and vali-
ating uniform standards across the world, so that clinical
utcomes in many cardiovascular entities including heart
ailure can meaningfully be compared, may take many years.
he challenge is daunting but necessary; the idea is old but
he need is timely.
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